RxPG News XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!  

Medical Research Health Special Topics World
 
  Home
 
 Careers 
 Dental
 Medical
 Nursing
 
 Latest Research 
 Aging
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Psychiatry
 Public Health
 Radiology
 Rheumatology
 Surgery
 Urology
 Alternative Medicine
 Medicine
 Epidemiology
 Sports Medicine
 Toxicology
 
 Medical News 
 Awards & Prizes
 Epidemics
 Health
 Healthcare
 Launch
 Opinion
 Professionals
 
 Special Topics 
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
 
 DocIndia 
 Reservation Issue
 Overseas Indian Doctor

Last Updated: May 20, 2007 - 10:48:48 AM
News Report
America Channel

subscribe to America newsletter
America

   EMAIL   |   PRINT
Another potential breast cancer treatment identified
May 13, 2007 - 3:57:24 PM
The animals were treated for just two weeks, but the beneficial effects were seen for two months.

Article options
 Email to a Friend
 Printer friendly version
 America channel RSS
 More America news
[RxPG] New York, May 13 - Canadian scientists claim to have found a treatment, which could block the action of an enzyme that fuels the growth of breast cancer.

The enzyme PTP1B appears to fuel tumour growth and drugs that block this enzyme may be useful in treating the disease. About 40 percent of human breast cancers have been shown to have excessively high levels of this enzyme.

Michel Tremblay and colleagues at McGill University in Montreal found that deleting PTP1B in mice led to a significant delay in the onset of breast tumours. It also prevented the secondary development of tumours in the lungs, reported the online edition BBC News.

Over-expression of PTP1B has already been implicated in the development of diabetes and obesity, where it shuts down insulin receptors, leading a number of drug companies to develop compounds to block its action.

The animals were treated for just two weeks, but the beneficial effects were seen for two months.

Tremblay said: 'This study is very exciting for cancer patients. However, it won't cure cancer alone. It's another tool to tackle cancers.





Related America News
Run to support fight against kidney disease
Mexican footballer banned for life for doping
Ranbaxy gets FDA approval for allergy drug
Sunita Williams assembles special space walk tool
Simpson misses charity benefit
Chronic pain may impair your memory
Silicon Valley companies provide technology for latest 'Shrek' film
Israel threatens to take 'other military actions' in Gaza
'World bank can now refocus on poverty in South Asia'
Microsoft buys ad-firm Aquantive for $6 bn

Subscribe to America Newsletter
E-mail Address:

 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
© All rights reserved 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us